SCHEDULE: Artelo Biosciences Stakeholder Reports 4.8% Ownership

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, reported a combined beneficial ownership of 4.8% in Artelo Biosciences, Inc. common stock as of June 30, 2026.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the 'Reporting Persons') have filed an amendment to their Schedule 13G.
• As of June 30, 2026, the Reporting Persons collectively beneficially owned 173,914 shares of Artelo Biosciences, Inc. common stock.
• This ownership stake represents approximately 4.8% of the company's outstanding common stock.
• The shares are held through a warrant owned by Intracoastal Capital LLC.
• The filing indicates that the Reporting Persons do not hold these shares for the purpose of influencing or changing the control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to its nature as a Schedule 13G, indicating a passive stake rather than active investment or positive strategic development.

Positives

• The filing clarifies the ownership stake of key individuals and an entity, providing transparency to the market.
• The reported ownership of 4.8% is below the threshold that typically triggers more stringent reporting requirements or activist investor concerns.

Negatives

• The filing does not indicate any new investment or strategic initiative by the reporting persons, suggesting a passive holding.
• The ownership is tied to a warrant, which may imply a contingent or less direct form of investment compared to direct share ownership.

Risks

• The primary risk is that the passive nature of this stake could be interpreted as a lack of confidence or conviction in the company's future prospects by these investors.
• Future exercise or disposition of the warrant could lead to increased selling pressure on the stock.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from the company. It is a disclosure of ownership by third parties.

Management Comments

• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and individuals who acquire a significant, but typically passive, stake in a public company. This filing indicates a notable but not controlling interest in Artelo Biosciences.

Comparison to Industry Standards

• In the biotechnology sector, ownership stakes of 5% or more are common for institutional investors, hedge funds, and venture capital firms. However, a Schedule 13G filing implies a passive investment strategy, distinguishing it from activist investors who might file a Schedule 13D.
• Companies like Artelo Biosciences, often in earlier stages of development, may see such filings from entities that provide capital through instruments like warrants, as seen here with Intracoastal Capital LLC.

Stakeholder Impact

• Shareholders gain clarity on a significant passive ownership block, which may influence market perception of the stock's float and potential trading dynamics.
• The company's management is made aware of the reporting persons' stake and their stated intention not to influence control.

Next Steps

• The Reporting Persons will continue to hold their stake in Artelo Biosciences, Inc.
• Future actions regarding the warrant and the underlying shares will be subject to market conditions and the Reporting Persons' investment strategies.

Key Dates

Keywords

Artelo Biosciences, Schedule 13G, Beneficial Ownership, Intracoastal Capital, Warrant, SEC Filing, Equity Stake